Modified POTE Peptides for Cancer Immunotherapy


POTE is a novel tumor antigen expressed in a variety of cancers including breast, prostate, colon, lung, ovary, and pancreas cancers.  POTE has limited expression in normal tissues and therefore a specific target for cancer treatments, including immunotherapy.  The researchers seek statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize immunogenic peptides. 

Antigen-specific cancer immunotherapy often relies on identification of epitopes expressed by cancer cells that can targeted by cytotoxic T cells (CTL).  However, the CTL repertoire against high-affinity cancer epitopes is often ineffective because cancer epitopes may share a similar structure to natural "self" antigens.  As a result, cancer cells are not recognized by CTLs and destroyed.  The enhanced POTE epitopes induce a stronger immune response than natural responses.  These modified epitopes are more effective at inducing CTL against POTE expressing cancer cells and have greater potential to serve as cancer vaccine targets.



Development Stage:
Discovery (Lead Identification)

Inventors:

Jay Berzofsky (NCI)  ➽ more inventions...

Yi-Hisang Huang (NCI)  ➽ more inventions...

Masaki Terabe (NCI)  ➽ more inventions...

Ira Pastan (NCI)  ➽ more inventions...


Intellectual Property:
US Application No. 13/610,421

Collaboration Opportunity:

Licensing and research collaboration


Licensing Contact:
John Hewes, Ph.D.
Email: John.Hewes@nih.gov
Phone: 240-276-5515

OTT Reference No: E-003-2010
Updated: Jun 19, 2018